Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

Faster, Cleaner, Better.

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Lipella Pharms Inc (LIPO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

Lipella Pharmaceuticals Announces CMO Retirement Tipranks - Fri Oct 10, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Lipella Pharmaceuticals,...

Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus GlobeNewswire - Thu Sep 18, 2025

All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profile Statistically significant improvements achieved across all efficacy endpoints at the 4-week...

Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus PR Newswire - Mon Sep 15, 2025

PITTSBURGH , Sept. 15, 2025 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (OTC: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company transforming care with innovative...

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting GlobeNewswire - Wed Jun 25, 2025

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market GlobeNewswire - Fri Jun 20, 2025

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology GlobeNewswire - Tue Jun 17, 2025

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development GlobeNewswire - Wed Jun 4, 2025

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting GlobeNewswire - Thu May 15, 2025

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” GlobeNewswire - Wed Apr 23, 2025

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025 GlobeNewswire - Tue Apr 22, 2025